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median Karnofsky (KPS) score prior to transplant was 90
(range: 70-100); those who received plerixafor (n¼88) ten-
ded to have lower KPS vs. G-CSF alone (n¼41; p¼.07). Median
age of the cohort was 54 years (range: 19-76), with HL pts
younger than NHL pts (median: 37 vs. 60 years). Ability to
collect >2x106 /kg CD34+ cells on day 1 was highly associ-
ated with achieving a total yield of >5x106 /kg CD34+ cells
(OR¼41.6; p<.001). Both collection goals were signiﬁcantly
associated with earlier time to ANC engraftment (p<.001). In
the 88 pts who received plerixafor (75 NHL pts), the median
number of doses was 2 (range: 1-3); 76% received their ﬁrst
dose on day 4 (range: 4-7). Patients who received day 4
plerixafor had signiﬁcantly lower CD34 counts on day 4 than
those that received G-CSF alone (p<.001). Plerixafor use was
highly associated with>2x106 /kg on ﬁrst collection (p¼.03),
but not with the total number of collections or the ability to
achieve a total yield of >5x106 /kg CD34+ cells. However,
whether or not pts got plerixafor on day 4 vs. later was
signiﬁcantly associated with sufﬁcient total CD34+ cell yield
(37% vs. 10%; p¼.016).
Conclusions: Pts who received planned plerixafor on day 4
were more likely to achieve the target yield despite having
risk factors for mobilization failure. Routine use of plerixafor
in lymphoma pts who are less likely to be poor mobilizers
may lead to fewer apheresis procedures, faster engraftment,
and shorter hospital stays. The potential economic beneﬁts of
this strategy warrant further investigation.Table 1
Data Summary
Variables Group A, N¼16 Group B, N¼16
Age* (yrs) 58 (39-72) 58 (49-68)
KPS* (%) 70 (60-80) 70 (60-80)
Creatinine Clearance
pre 2nd ASCT* (ml/min)
76 (42-129) 108 (44-218)
CR pre- 2nd ASCT [n (%)] 2 (12) 3 (14)
CD34+ cells infused for 2nd
ASCT* (x 106 cells/kg)
3.35 (2.2-10.7) 3.12 (2.79-12.04)
Febrile Neutropenia [n (%)] 10 (63) 16 (100)
In-patient stay for
2nd ASCT* (days)
15 (12-24) 23 (19-51)
CR at Day +100 post
2nd ASCT [n (%)]
2{ (14) 7x (47)
KPS- Karnofsky’s Performance score
CR- Complete response
ASCT- Autologous Stem cell transplant
* Values are median with range in parenthesis
{Day +100 response data not available for 2 patients in Group A
x Day +100 response data not available for 1 patient in Group B141
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Objetives: G-CSF has shown to shorten time to neutrophil
engraftment in autologous peripheral blood hematopoietic
stem cell transplantation (Auto-HSCT). Two ﬁlgrastim phar-
macological presentations exist for clinical use, non-pegy-
lated and pegylated. Our aim was to compare clinical
outcomes in using as support Peg-Filgrastim (PEG-F)or Fil-
grastim (F) in a group of adults undergoing autologous HSCT.
Methods: From 2010 to 2012, 69 adult patients underwent
Auto-HSTC in our BMT unit. Attending physician decided
the allocation to PEG-F or F. Other support measures
were standardized in all patients. An independent reviewer
collected data from medical records. Descriptive analyses
were carried-out as well as Kaplan-Meier survival estimates.
Results: From69 included subjects, 50 received PEG-F and 19
F. Median age was 46 vs 54 for PEG-F vs. F (P¼.05). There was
no difference by gender, body weight, diagnoses, condi-
tioning regimen, or CD34+ cells infused. Most common
diagnoses were Multiple Myeloma (48%) and Hodgkin lym-
phoma (28%). In concordance with diagnoses, Melphalan
(52%) and BEAM (46%) were the conditioning regimens most
commonly used. Median CD34+ (x106)/Kg preserved were
4.3 for PEG-F vs. 3.9 for F, (P¼.61). Median initiation of PEG-F
was 7 days after cell infusion compared to 3 days for F; P<.01.
We did not have transplant mortality death. Neutropenicfever was equal among groups (58% vs 47%). Median
number of days to achieve 500 neutrophils was 12 vs 11
(PEG-F vs F); P<.01. All patients showed neutrophil and
platelet engraftment.
Conclusions: We did not ﬁnd clinically relevant differences
among the effects of the two pharmacological ﬁlgrastim
presentations. We also found that 4 day difference in starting
the drug only represented 1 day of delay in neutrophil
engraftment without clinical repercussions. Now, we
considered changing our clinical practice by introducing
PEG-F for all patients, taking into consideration ease of
application and economical consideration.142
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Background: Salvage ASCT is increasingly utilized for
eligible MM patients (pts). High dose melphalan (HDM) is
the standard conditioning used for 1st ASCT. Despite con-
cerns for resistance, HDM is predominantly used as condi-
tioning regimen for 2nd / or salvage ASCT. BEAM (Carmustine,
etoposide, Ara-C and Melphalan) has shown superior PFS
and OS compared to HDM during 1st ASCT for MM pts. We
conducted a single institution retrospective analysis to
evaluate response and toxicity with BEAM conditioning in
2ndASCT.
Methods: Thirty two pts who received 2nd ASCT for MM
(2007-2013) were identiﬁed. Sixteen pts received HDM (140-
200mg/m2; Group A) and an equal number received BEAM
(carmustine 300 mg/m2, etoposide 100 mg/m2, cytarabine
100 mg/m2, and melphalan 140 mg/m2; Group B). Patient
characteristics, toxicity and response at day 100 were
collected and compared between the 2 groups. Fischer’s
Preparative regimens
BEAM D-5 D-4 D-3 D-2 D-1
Etoposido 200-300 mgs/m2/day X X X X
BiCNU 300 mgs/m2/day X
Citarabine 300 mgs/m2/day X X X
Melfalan 140 mgs/m2/day X
CBV
Cyclosphaphamide 2.000 mgs/m2/day X X X
BiCNU 300 mgs/m2/day X
Etoposide 300 mgs/m2/day X X X
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compare responses and toxicities.
Results: The median age of the patients was 58 yrs (range:
39-72) in Group A and 58 yrs (range: 49-68) in Group B.
Group A had more female pts (56% vs 25%) and a decreased
baseline renal function (median creatinine clearance 76 vs
108 ml/min) compared to Group B. There was no signiﬁcant
difference in disease status pre-2nd ASCT between the 2
groups. Salvage therapywas given to 12 pts in group A and 16
pts in group B. The median time between 2 ASCTs were 29
(range: 3-67) months in group A vs 35.5 (range: 18-58)
months in group B. All patients received stem cells which
were collected and cryopreserved prior to the 1stASCT. At day
+100, seven patients from Group B had CR compared to 2
from group A (p¼.11) (Table 1). Patients who received BEAM
had higher incidence of febrile neutropenia (16 vs 10 pts) and
longer hospitalization (23 vs 15 days, p <.0001). Other
toxicities were not signiﬁcantly different between these
groups.
Conclusion: BEAM seems to be a viable and tolerable con-
ditioning regimen for 2ndASCT in MM pts. Further analyses
including PFS and OS are planned to better deﬁne the two
groups.143
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Small series have shown that it is possible perform autolo-
gous hematopoietic transplant in lymphoma patient without
cryopreservation. In most of them, CBV like or BEAM liker-
egimen were used, but with important modiﬁcations of the
intensity of dose delivered, or using different drugs . We
present our experience in a large group of lymphoma pa-
tients using non-cryopreserved stem cells after administra-
tion of BEAM or CBVwithout alteration of the total amount of
chemotherapy of these regimens.
The mobilization was done with ﬁlgrastin 5 mg/kg/BID for
ﬁve to six days, after that, one or two leukopheresis of 3 to 5
blood volume was done; the cells were stored at 4oC, 6 days
for ﬁrst leukopheresis, and 5 for the second one. The pre-
parative regimen began in the evening of the last pheresis,
this was the day e 5. All patients received ﬁlgrastim or
pegﬁlgrastim after the transplant82 ptes in whom were
collected at least 1.0 x 10(6) CD 34/kg (X: 2.5) were trans-
planted; 49 were men, median age was 36 Y (11-65), 42 had
Hodgkin disease and 40 had lymphoma, the totality of them
were in CR2 or beyond. 65 received BEAM and 17 CBV. The
median viability of the cells after 6 days of refrigeration
(trypan blue exclusion) was 82% (range 66-90). All patients
had fast and complete neutrophil engraftment; median time
to achieve 500/ul or more was 12 days (9-23), 79 were
evaluable for thrombopoiesis, 78 of them had a self- sus-
tained platelets count of 20.000 or more at a median of 17
days (range 9-50). There has not been secondary engraft-
ment failure.
The tolerance and efﬁcacy of the BEAM and CBV adminis-
tered in 5 days was good; the transplant related mortality
was 3.6% and the Kaplan Meir estimate for OS at 36 months
was 65% and 58% for patients with Hodgkin and lymphoma
respectively.We conclude; the use of non-cryopreserved stem cell for
supporting autologous transplant after a BEAM or CBV con-
ditioning is feasible, safe, and produce a fast, complete and
sustained hematopoiesis. This simple procedure is a good
alternative for saving costs and it can expand the number
of lymphoma patients who would receive the beneﬁt of
tranplant.144
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Background: Standard initial therapy for a minority of
patients with systemic AL amyloidosis is risk-adapted
melphalan and stem cell transplant (SCT) with SC mobiliza-
tion often accomplished with high dose G-CSF (16mg/kg/d).
Based on the phase III experience in MM, we investigated the
combination of G-CSF and Plerixafor for stem cell mobiliza-
tion in AL. We report an update of our experience with this
mobilization approach.
Methods: Patients were diagnosed by standard criteria with
tissue biopsies showing amyloidosis. They were mobilized
and collected between 4/16/12 and 9/11/13 with G-CSF 10mg/
kg/d subcutaneously (SC) for 5 days (and continued through
collection) and Plerixafor, adjusted for renal function, start-
ing on day 4 until collection was completed.
Results: We report on 12 patients whose median age at
mobilization was 58 yrs (range 46-72), 58% of whom were
men. Median number of organs involved was 2 (range 1-4),
most frequently the kidneys (n¼9) and the heart (n¼8).
Median time from diagnosis to mobilization was 7.5 mths
(range 2-123). 9 patients had prior bortezomib-based ther-
apy with a median of 3 cycles (range 0-6). One had received a
SCT 10 years prior and relapsed, and one was 1 yr s/p
orthotopic heart transplant. 5 patients had a creatinine of 
1.5 mg/dL including 2 on hemodialysis. The target CD34+ cell
dose was 10 x 106 CD34/kg for all but one patient due to the
history of prior SCT. The median number of collections was 2
(range 2-3). On day one, a median of 3.6 x106 CD34/kg (0.4-
13.8x106) was collected and on day two, 6.4 x106 (2.7-
19x106). The median total CD34+ cells collected per kg was
13.8x106 (5-18x106). No signiﬁcant toxicities were observed
with Plerixafor. 2 patients had grade 1 bleeding from the
catheter site during apheresis and one had dyspnea with
suspected ﬂuid overload which responded to furosemide.
All patients went on to receive high dose chemotherapy
with melphalan followed by autologous SCT. The median
stem cell dose infused was 7.7x 106 CD34/kg and median
days to ANC > 500 was 11 (10-22), to platelets > 20K
untransfused was 22 (15-44) and to lymphocytes > 500/ml
was 14.5 (11-25). One patient who had VOD and persistent
